Clinical Trials/Drug Trials News

Stroke Study Reveals Key Target For Improving Treatment

Mon, 23 Jun 2008 13:20:04 GMT

For over a decade, the drug called tPA has proven its worth as the most effective emergency treatment for the most common kind of stroke.

Full text

Bowel Prep Oral Sodium Phosphate Equal To Fasting Before Capsule Endoscopy For Obscure GI Bleeding

Sat, 21 Jun 2008 06:40:05 GMT

According to a new study from researchers in France, bowel preparation with oral sodium phosphate for capsule endoscopy in patients with obscure gastrointestinal (GI) bleeding is no better at cleansing the small bowel than the standard method of preparation, which is an eight-hour fast before the procedure.

Full text

Poor Children More Likely To Develop Diabetes As Adults

Sat, 21 Jun 2008 06:40:03 GMT

Diabetes strikes harder at those who were poor as children, according to a new study that spans more than three decades.

Full text

Forest Laboratories Announces Positive Results From Phase III Clinical Studies Of Ceftaroline For The Treatment Of Complicated Skin And Skin Structure

Sat, 21 Jun 2008 06:40:03 GMT

Forest Laboratories, Inc. (NYSE: FRX) announced positive results from two globally conducted, multi-center Phase III studies of ceftaroline, a broad-spectrum cephalosporin with activity against gram-positive bacteria, such as MRSA and gram negative bacteria, for the treatment of complicated skin and skin structure infections (cSSSI).

Full text

US WorldMeds Completes Phase III Trial Of Lofexidine For Treatment Of Opiate Withdrawal Symptoms

Fri, 20 Jun 2008 02:40:07 GMT

US WorldMeds, a Kentucky-based specialty pharmaceutical company, announced that a recently completed Phase III clinical trial investigating the use of lofexidine hydrochloride (Lofexidine) for the treatment of opiate withdrawal symptoms in patients undergoing opiate detoxification has shown that.

Full text

Long-Term Safety Data On Lialda TM mesalamine For Patients With Ulcerative Colitis Published In Leading GI Journal

Fri, 20 Jun 2008 02:40:04 GMT

Shire Limited (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, has announced the publication of data from a randomized, long-term safety and tolerability study (study 303) of ulcerative colitis (UC) drug Lialda(TM) (mesalamine).

Full text

Two-Year Clinical Trial Findings Show Significant And Persistent Reduction In Blood Pressure With CVRx R Rheos R Hypertension Therapy

Fri, 20 Jun 2008 02:40:02 GMT

The first available two-year data from the European clinical trial evaluating the Rheos Hypertension (HT) System were presented at Hypertension Berlin 2008.

Full text

New Technology May Prevent Vitamin B12 Deficient Seniors And Vegetarians From Needing Injections

Wed, 18 Jun 2008 23:20:12 GMT

Pharmaceutical scientists from across the globe present health discoveries at the American Association of Pharmaceutical Scientists' National Biotechnology ConferenceFor those patients who receive the nearly 40 million intramuscular injections per year to treat their B12 deficiency, a new oral option may soon exist.

Full text

Epratuzumab Reduced Disease Activity And Steroid Use In Patients With Moderate And Severe Flaring SLE

Wed, 18 Jun 2008 23:20:11 GMT

UCB has announced that data presented recently show that epratuzumab treatment demonstrated clinically meaningful improvements in moderate and severe flaring systemic lupus erythematosus (SLE) patients.

Full text

Long-Term Safety Data On Lialda Published In Leading GI Journal

Wed, 18 Jun 2008 23:20:10 GMT

Shire Limited (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, has announced the publication of data from a randomized, long-term safety and tolerability study (study 303) of ulcerative colitis (UC) drug Lialda™

Full text